23 results
8-K
EX-99.1
IMNM
Immunome, Inc.
12 Aug 24
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
4:05pm
therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership
8-K
EX-99.1
IMNM
Immunome, Inc.
13 Feb 24
Results of Operations and Financial Condition
4:10pm
for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference
8-K
EX-99.1
IMNM
Immunome, Inc.
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
through combining rigorously selected targets with innovative linker-payload platforms. We believe that the linker-payload technology that underlies
8-K
EX-99.1
IMNM
Immunome, Inc.
9 Nov 23
Immunome Reports Third Quarter 2023 Financial Results
4:52pm
Officer of Immunome. “There remains a significant need for innovative and best in class treatments to address unmet medical needs for cancer patients
424B3
kgh4p5ca5aqwbl12xh
28 Aug 23
Prospectus supplement
9:10am
S-4/A
s4sx ushco
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
S-4
5vem p7trv0
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
PRE 14A
1df8iv wgh
7 Apr 23
Preliminary proxy
6:29am
8-K
EX-99.1
4waugpxwsrl77
17 Jun 21
Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D. to Board of Directors
4:55pm
DEF 14A
gjocxzb97nj3ksia
16 Apr 21
Definitive proxy
3:35pm
10-K
mnkdpwbu81bk0qx4ar
25 Mar 21
Annual report
5:01pm
424B4
uwc1mqm0 w4az2d34zsu
5 Oct 20
Prospectus supplement with pricing info
5:10pm